Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$225.16 -2.4%	$233.02	$149.04 ▼ $251.71	$542.42B	0.27	7.02 million shs	13.90 million shs
LLY Eli Lilly and Company	$1,105.37 -1.9%	$955.92	$623.78 ▼ $1,149.10	$1.04T	0.48	3.09 million shs	4.60 million shs
NVO Novo Nordisk A/S	$45.57 +0.1%	$40.98	$35.12 ▼ $81.44	$203.51B	0.77	14.57 million shs	10.97 million shs
PFE Pfizer	$26.18 +0.2%	$26.77	$23.06 ▼ $28.75	$149.21B	0.35	33.36 million shs	48.26 million shs
REGN Regeneron Pharmaceuticals	$614.78 -1.1%	$719.15	$476.49 ▼ $821.11	$64.99B	0.3	1.01 million shs	2.19 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	-2.54%	-4.05%	-0.94%	-9.50%	+47.62%
LLY Eli Lilly and Company	-1.89%	+3.64%	+29.79%	+5.23%	+53.82%
NVO Novo Nordisk A/S	+0.15%	+1.48%	+13.14%	+21.54%	-33.60%
PFE Pfizer	+0.11%	+1.02%	-0.32%	-5.16%	+12.96%
REGN Regeneron Pharmaceuticals	-1.08%	-3.77%	-10.43%	-21.35%	+3.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$225.16 -2.4%	$233.02	$149.04 ▼ $251.71	$542.42B	0.27	7.02 million shs	13.90 million shs
LLY Eli Lilly and Company	$1,105.37 -1.9%	$955.92	$623.78 ▼ $1,149.10	$1.04T	0.48	3.09 million shs	4.60 million shs
NVO Novo Nordisk A/S	$45.57 +0.1%	$40.98	$35.12 ▼ $81.44	$203.51B	0.77	14.57 million shs	10.97 million shs
PFE Pfizer	$26.18 +0.2%	$26.77	$23.06 ▼ $28.75	$149.21B	0.35	33.36 million shs	48.26 million shs
REGN Regeneron Pharmaceuticals	$614.78 -1.1%	$719.15	$476.49 ▼ $821.11	$64.99B	0.3	1.01 million shs	2.19 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	-2.54%	-4.05%	-0.94%	-9.50%	+47.62%
LLY Eli Lilly and Company	-1.89%	+3.64%	+29.79%	+5.23%	+53.82%
NVO Novo Nordisk A/S	+0.15%	+1.48%	+13.14%	+21.54%	-33.60%
PFE Pfizer	+0.11%	+1.02%	-0.32%	-5.16%	+12.96%
REGN Regeneron Pharmaceuticals	-1.08%	-3.77%	-10.43%	-21.35%	+3.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.74	Moderate Buy	$253.04	12.38% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,227.00	11.00% Upside
NVO Novo Nordisk A/S	2.13	Hold	$65.56	43.86% Upside
PFE Pfizer	2.20	Hold	$28.82	10.08% Upside
REGN Regeneron Pharmaceuticals	2.70	Moderate Buy	$792.65	28.93% Upside

Current Analyst Ratings Breakdown

Latest PFE, LLY, JNJ, REGN, and NVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2026	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$27.00
5/26/2026	LLY Eli Lilly and Company	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,133.00 ➝ $1,251.00
5/26/2026	LLY Eli Lilly and Company	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1,119.00
5/22/2026	LLY Eli Lilly and Company	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1,283.00
5/21/2026	LLY Eli Lilly and Company	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,350.00
5/21/2026	LLY Eli Lilly and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/21/2026	LLY Eli Lilly and Company	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$1,300.00 ➝ $1,330.00
5/19/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
5/19/2026	REGN Regeneron Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$1,057.00 ➝ $875.00
5/18/2026	REGN Regeneron Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$900.00 ➝ $730.00
5/18/2026	REGN Regeneron Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$796.00 ➝ $778.00

(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$94.19B	5.75	$14.11 per share	15.96	$33.73 per share	6.68
LLY Eli Lilly and Company	$65.18B	15.97	$25.14 per share	43.96	$33.13 per share	33.36
NVO Novo Nordisk A/S	$46.80B	4.35	$4.69 per share	9.72	$7.12 per share	6.40
PFE Pfizer	$62.58B	2.38	$4.40 per share	5.95	$15.86 per share	1.65
REGN Regeneron Pharmaceuticals	$14.34B	4.53	$41.96 per share	14.65	$297.23 per share	2.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$26.80B	$8.65	26.03	17.90	2.21	21.83%	32.60%	13.29%	7/15/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	39.27	24.94	1.21	34.98%	105.77%	23.76%	8/5/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.26	10.70	13.25	4.06	37.23%	63.31%	22.19%	8/5/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	19.99	9.15	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)
REGN Regeneron Pharmaceuticals	$4.50B	$41.04	14.98	14.79	1.36	29.65%	13.16%	10.17%	7/30/2026 (Estimated)

Latest PFE, LLY, JNJ, REGN, and NVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2026	Q1 2026	NVO Novo Nordisk A/S	$0.87	$1.04	+$0.17	$1.69	$10.86 billion	$10.85 billion
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
4/30/2026	Q1 2026	LLY Eli Lilly and Company	$6.97	$8.55	+$1.58	$8.26	$17.82 billion	$19.80 billion
4/29/2026	Q1 2026	REGN Regeneron Pharmaceuticals	$8.91	$9.47	+$0.56	$6.75	$3.48 billion	$3.61 billion
4/14/2026	Q1 2026	JNJ Johnson & Johnson	$2.68	$2.70	+$0.02	$2.14	$23.60 billion	$24.06 billion
3/31/2026	Q1 2026	NVO Novo Nordisk A/S	N/A	$1.0270	N/A	$1.69	N/A	$10.85 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$5.36	2.38%	+5.25%	61.97%	64 Years
LLY Eli Lilly and Company	$6.92	0.63%	+15.18%	24.58%	11 Years
NVO Novo Nordisk A/S	$1.75	3.84%	+21.74%	41.08%	N/A
PFE Pfizer	$1.72	6.57%	-13.20%	131.30%	16 Years
REGN Regeneron Pharmaceuticals	$3.76	0.61%	N/A	9.16%	N/A

Latest PFE, LLY, JNJ, REGN, and NVO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.69%	5/15/2026	5/15/2026	6/10/2026
4/14/2026	JNJ Johnson & Johnson	quarterly	$1.34	2.33%	5/26/2026	5/26/2026	6/9/2026
4/29/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.58%	5/20/2026	5/20/2026	6/4/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.46	1.03	0.77
LLY Eli Lilly and Company	1.26	1.50	1.10
NVO Novo Nordisk A/S	0.59	0.79	0.56
PFE Pfizer	0.67	1.25	0.94
REGN Regeneron Pharmaceuticals	0.06	3.57	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
PFE Pfizer	68.36%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%
PFE Pfizer	0.62%
REGN Regeneron Pharmaceuticals	6.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.40 billion	Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable
REGN Regeneron Pharmaceuticals	15,410	105.72 million	98.35 million	Optionable

PFE, LLY, JNJ, REGN, and NVO Headlines

Recent News About These Companies

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?

May 29 at 3:16 PM | finance.yahoo.com

Regeneron Expands Into Pulmonary Hypertension With New Phase 2 Trial for REGN13335

May 29 at 12:50 PM | tipranks.com

Regeneron Steps Into CAR T for Advanced Prostate Cancer With New Phase 1 Trial

May 29 at 12:50 PM | tipranks.com

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?

May 29 at 12:31 PM | zacks.com

National Pension Service Acquires 82,853 Shares of Regeneron Pharmaceuticals, Inc. $REGN

May 29 at 6:37 AM | marketbeat.com

Fideuram Asset Management Ireland dac Invests $10.12 Million in Regeneron Pharmaceuticals, Inc. $REGN

May 29 at 4:28 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Geode Capital Management LLC

May 29 at 3:58 AM | marketbeat.com

Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

May 28 at 4:00 PM | globenewswire.com

Regeneron And Parabilis Target Undruggable Proteins As Valuation Draws Interest

May 28 at 1:39 PM | finance.yahoo.com

These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth

May 28 at 11:04 AM | 247wallst.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

May 28 at 10:00 AM | prnewswire.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of "Moderate Buy" from Brokerages

May 28 at 2:06 AM | americanbankingnews.com

Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results

May 27 at 6:05 PM | finance.yahoo.com

Allstate Corp Has $5.92 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

May 27 at 3:09 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

May 26, 2026 | globenewswire.com

Canaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing Event

May 26, 2026 | finance.yahoo.com

Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink?

May 26, 2026 | barchart.com

Legal & General Group Plc Sells 27,332 Shares of Regeneron Pharmaceuticals, Inc. $REGN

May 26, 2026 | marketbeat.com

Prospera Financial Services Inc Decreases Stake in Regeneron Pharmaceuticals, Inc. $REGN

May 26, 2026 | marketbeat.com

Jefferies Financial Group Inc. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

May 26, 2026 | marketbeat.com

Regeneron (REGN) Enters $2.32B Collaboration With Parabilis to Target ‘Undruggable’ Proteins

May 25, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PFE, LLY, JNJ, REGN, and NVO Company Descriptions

Johnson & Johnson NYSE:JNJ

$225.16 -5.64 (-2.44%)

Closing price 05/29/2026 03:59 PM Eastern

Extended Trading

$225.42 +0.25 (+0.11%)

As of 05/29/2026 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$1,105.37 -21.43 (-1.90%)

Closing price 05/29/2026 03:59 PM Eastern

Extended Trading

$1,105.00 -0.37 (-0.03%)

As of 05/29/2026 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$45.57 +0.06 (+0.14%)

Closing price 05/29/2026 03:59 PM Eastern

Extended Trading

$45.56 -0.01 (-0.03%)

As of 05/29/2026 07:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer NYSE:PFE

$26.18 +0.04 (+0.16%)

Closing price 05/29/2026 03:59 PM Eastern

Extended Trading

$26.15 -0.03 (-0.13%)

As of 05/29/2026 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Regeneron Pharmaceuticals NASDAQ:REGN

$614.78 -6.74 (-1.08%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$616.12 +1.34 (+0.22%)

As of 05/29/2026 07:51 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, LLY, JNJ, REGN, and NVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, LLY, JNJ, REGN, and NVO Earnings

Compare Dividends

Latest PFE, LLY, JNJ, REGN, and NVO Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, LLY, JNJ, REGN, and NVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PFE, LLY, JNJ, REGN, and NVO Company Descriptions

Johnson & Johnson NYSE:JNJ

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

Pfizer NYSE:PFE

Regeneron Pharmaceuticals NASDAQ:REGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools